Skip to main content
Atrás
Watch Compare

Rani Therapeutics Holdings, Inc.

Calidad de datos: 100%
RANI
Nasdaq Manufacturing Chemicals
$0.78
▼ $0.06 (-6.73%)
Cap. Mercado: 77.30 M
Precio
$0.78
Cap. Mercado
77.30 M
Rango del Día
$0.77 — $0.84
Rango de 52 Semanas
$0.39 — $3.87
Volumen
1,196,221
Apertura $0.84
Promedio 50D / 200D
$1.22
36.39% below
Promedio 50D / 200D
$1.07
27.69% below

Quick Summary

Puntos Clave

Revenue declined -11.95% annually over 5 years
Negative free cash flow of -18.80 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 70.80%
Capital efficient — spends only 5.39% of revenue on capex

Crecimiento

Revenue Growth (5Y)
-11.95%
Below sector avg (1.82%)
Revenue (1Y)58.85%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
N/A
ROICN/A
Net Margin-1817.09%
Op. Margin-2345.99%

Seguridad

Debt / Equity
N/A
Current Ratio0.26
Interest Coverage-13.25

Valoración

PE (TTM)
-2.61
Below sector avg (-1.47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1364 pares)
Métrica Acción Mediana del Sector
P/E -2.6 -1.5
P/B — 1.6
ROE % — -53.5
Net Margin % -1817.1 -41.5
Rev Growth 5Y % -12.0 1.8
D/E — 0.3

ETFs Holding This Stock

BRSIX BRSIX
0.06% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 58.85% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -11.95% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1.63 M Net Income (TTM) -29.67 M
ROE N/A ROA -219.50%
Gross Margin N/A Operating Margin -2345.99%
Net Margin -1817.09% Free Cash Flow (TTM) -18.80 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0.26
Interest Coverage -13.25 Asset Turnover 0.12
Working Capital -14.19 M Tangible Book Value -7.86 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2.61 Forward P/E N/A
P/B Ratio N/A P/S Ratio 47.34
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -24.32%
Market Cap 77.30 M Enterprise Value 86.91 M
Per Share
EPS (Diluted TTM) -0.45 Revenue / Share 0.02
FCF / Share -0.19 OCF / Share -0.19
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 5.39% FCF Conversion 63.36%
SBC-Adj. FCF -32.40 M Growth Momentum 70.80

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.63 M 1.03 M — 0.0 2.72 M
Net Income -29.67 M -30.02 M -33.97 M -30.59 M -8.33 M
EPS (Diluted) -0.45 -1.05 -1.33 -1.28 —
Gross Profit — — — — —
Operating Income -38.31 M -53.31 M -66.10 M -63.45 M -51.60 M
EBITDA — — — — —
R&D Expenses 20.21 M 26.68 M 39.62 M 36.61 M 26.48 M
SG&A Expenses — — — — —
D&A 900,000.0 1.03 M 822,000.0 548,000.0 —
Interest Expense 2.89 M 5.03 M 5.09 M 1.07 M 466,000.0
Income Tax 0.0 0.0 0.0 70,000.0 41,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 58.62 M 36.63 M 57.92 M 108.03 M 124.21 M
Total Liabilities 17.11 M 33.14 M 32.47 M 34.02 M 2.64 M
Shareholders' Equity 33.01 M 1.99 M 12.87 M 36.86 M 47.41 M
Total Debt 0.0 25.00 M 30.00 M 30.00 M 2.41 M
Cash & Equivalents 18.62 M 3.76 M 5.86 M 27.01 M 117.45 M
Current Assets 53.32 M 29.74 M 50.85 M 100.92 M 119.60 M
Current Liabilities 12.67 M 19.89 M 7.99 M 4.82 M 2.64 M